Sign in to view content

BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)

Michael A. Singer, MD

Video
Published 2024

Related

Hereditary Retinal Disease & Genetics Take-Home Panel
David Sarraf, MD
Annual Meeting Talks
2019
BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Michael A. Singer, MD
Updates from the Field
2024
Intravitreal Injection of Allogeneic Human Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa: Results from the Phase 2b Trial
Anthony Joseph, MD
Annual Meeting Talks
2020

Category: Hereditary Retinal Disease & Genetics

See more